GRI is a development stage biotech company fundamentally changing the way inflammatory disease is treated. GRI’s Natural Killer T (NKT) cell-based therapies are being developed for liver disease and acute liver failure. NKT cells share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 NKT cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. GRI’s lead program, GRI-0621, is an inhibitor of type I NKT cells and is being developed as a novel oral therapeutic for acute liver failure.